Enasidenib (AG-221) | Mutant IDH2 Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1446502-11-9
Formula :	C₁₉H₁₇F₆N₇O
M.W :	473.38
SMILES Code :	CC(O)(C)CNC1=NC(C2=NC(C(F)(F)F)=CC=C2)=NC(NC3=CC(C(F)(F)F)=NC=C3)=N1
Synonyms :	AG-221; CC-90007
MDL No. :	MFCD29472245
InChI Key :	DYLUUSLLRIQKOE-UHFFFAOYSA-N
Pubchem ID :	89683805

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P280-P305+P351+P338

AML cells	1 μM		To evaluate the effect of Enasidenib on AML cell differentiation	PMC6925974
MOLM14 IDH1 R132H	2 µM	24 hours to 2 weeks	Evaluate the effect of IDH1 mutant inhibitor on 2-HG levels and mitochondrial activities, showing significant reduction in 2-HG but maintenance or increase in mitochondrial activities	PMC7995203
HL60 IDH1 R132H	2 µM	24 hours to 2 weeks	Evaluate the effect of IDH1 mutant inhibitor on 2-HG levels and mitochondrial activities, showing significant reduction in 2-HG but maintenance or increase in mitochondrial activities	PMC7995203
CDS23 cells	>100 μM (IC50)	72 hours	CDS23 cells were fully resistant to enasidenib with IC50>100 μM.	PMC10990714
CDS11 cells	63.53 μM (IC50)	72 hours	CDS11 cells were partially resistant to enasidenib with IC50 of 63.53 μM.	PMC10990714
L2975 cells	73.53 μM (IC50)	72 hours	L2975 cells were partially resistant to enasidenib with IC50 of 73.53 μM.	PMC10990714
SW1353 cells	49.47 μM (IC50)	72 hours	SW1353 cells showed intermediate sensitivity to enasidenib with IC50 of 49.47 μM.	PMC10990714
CDS17 cells	16.65-22.65 μM (IC50)	72 hours	Enasidenib significantly reduced the viability of CDS17 cells with IC50 ranging from 16.65 to 22.65 μM.	PMC10990714
CB-CD34+ cells	1-25 μM	8 days	Enhanced erythroid differentiation, indicated by an increase in the percentage of CD71+GPA+ cells	PMC7108889
Idh2R140Q/NHD13 thymocytes	5 or 10 μM		To evaluate the effect of AG-221 on the proliferation of Idh2R140Q/NHD13 DN cells, showing a marked decrease in leukemic cell proliferation.	PMC8487989
Primary murine hematopoietic stem/progenitor cells	50 nM		Evaluate the response of IDH2 R140Q co-expressed with wildtype, Q316E, or I319M to enasidenib	PMC6121718
Ba/F3 cells	1, 10, 100 nM		Evaluate the response of IDH2 R140Q co-expressed with wildtype, Q316E, or I319M to enasidenib	PMC6121718
Idh2R140Q/NHD13 thymocytes	5 or 10μM		To evaluate the effect of AG-221 on the proliferation of Idh2R140Q/NHD13 DN cells, showing a marked decrease in leukemic cell proliferation.	PMC8487989

Nude mice	T-CDS17#1 xenograft model	Oral	35 mg/kg	Twice daily for 21 days	Enasidenib treatment completely inhibited tumor growth and even caused tumor regressions.	PMC10990714
Mice	Idh2 R140Q mutant mice	Oral gavage	40 mg/kg	Twice daily for 2 or 4 weeks	Evaluate the response of IDH2 Q316E mutation to enasidenib treatment	PMC6121718

{[proInfo.proName]}

CAS No.: 1446502-11-9

{[proInfo.proName]}

CAS No.: 1446502-11-9

Alternative Products

Product Details of Enasidenib

Safety of Enasidenib

Isoform Comparison

Biological Activity

Protocol

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT04573582	Hepatic Impairment	PHASE1	COMPLETED	2023-03-08	Local Institution - 002, Miami... More >>, Florida, 33136, United States\|Local Institution - 003, Orlando, Florida, 32809, United States\|Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, 37920, United States Less <<
NCT03515512	Acute Myeloid Leukemia\|Chronic... More >> Myelomonocytic Leukemia Less <<	PHASE1	COMPLETED	2023-02-13	Johns Hopkins Cancer Center, B... More >>altimore, Maryland, 21287, United States\|Massachusetts General Hospital, Boston, Massachusetts, 02214, United States\|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States\|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States Less <<
NCT05102370	Clonal Cytopenia of Undetermin... More >>ed Significance\|CCUS Clonal Cytopenia of Undetermined Significance Less <<	PHASE1	ACTIVE_NOT_RECRUITING	2025-10-06	Mayo Clinic (Data Collection O... More >>nly), Rochester, Minnesota, 55905, United States\|Washington University (Data Collection and Specimen Analysis), Saint Louis, Missouri, 63110, United States\|Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, 07920, United States\|Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, 07748, United States\|Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale, New Jersey, 07645, United States\|Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities), Commack, New York, 11725, United States\|Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, 10604, United States\|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, 10065, United States\|Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, 11553, United States\|Cleveland Clinic (Data Collection Only), Cleveland, Ohio, 44195, United States\|Ohio State University (Data Collection Only), Columbus, Ohio, 43210, United States\|Oregon Health & Science University (Data Collection Only), Portland, Oregon, 97239, United States Less <<
NCT03744390	Myelodysplastic Syndromes\|Leuk... More >>emia Acute Myeloid Less <<	PHASE2	ACTIVE_NOT_RECRUITING	2026-03-18	H?pital André Mignot, Versaill... More >>es, LE Chesnay, 78157, France\|CH d'Angers/Service des Maladies du sang, Angers, 49933, France\|centre hospitalier Victor Dupouy, Argenteuil, 95107, France\|CH de la Cote Basque, Bayonne, 64109, France\|CHU de Bordeaux, Bordeaux, 33604, France\|CHU C?te de Nacre/Service d'Hématologie Clinique, Caen, 14033, France\|H?pital Henri Mondor, Créteil, 94010, France\|CHU de Grenoble, Grenoble, 38043, France\|CH Le Mans/Service d'hématologie Oncologie, Le Mans, 72000, France\|CH lyon, Lyon, 69495, France\|Institut Paoli Calmettes/Unité d'Hématologie 3, Marseille, 13009, France\|CHU Montpellier St Eloi, Montpellier, 34295, France\|GHR Mulhouse Sud-Alsace, Mulhouse, 68100, France\|CHU Nantes - H?tel Dieu/Service d'Hématologie Clinique, Nantes, 44093, France\|H?pital Archet 1/Service d'Hématologie Clinique, Nice, 06202, France\|CHU de Nimes, N?mes, 30029, France\|H?pital Saint Louis - Service d'hématologie séniors, Paris, 75010, France\|H?pital saint Antoine, Paris, 75571, France\|Centre Henri Becquerel/Département d'Hématologie, Rouen, 76 038, France\|Institut de cancérologie Lucien Neuwirth Saint priest en Jarez, Saint-Priest-en-Jarez, 42271, France\|Médecine Interne/IUCT Oncopole, Toulouse, 31059, France\|CHU de Tours, Tours, 37044, France Less <<
NCT01915498	Hematologic Neoplasms	PHASE1\|PHASE2	COMPLETED	2023-10-31	City Of Hope, Duarte, Californ... More >>ia, 91010-301, United States\|Stanford Cancer Center, Stanford, California, 94305, United States\|University Of Colorado Cancer Center, Aurora, Colorado, 80045, United States\|University of Miami Sylvester Cancer Center, Miami, Florida, 33136, United States\|Florida Cancer Specialists, Sarasota, Florida, 34232, United States\|Moffitt Cancer Center, Tampa, Florida, 33612, United States\|Northwestern University, Chicago, Illinois, 60611-3008, United States\|Massachusetts General Hospital, Boston, Massachusetts, 02117, United States\|Dana-Farber/Mass General Brigham Cancer Care, Inc, Boston, Massachusetts, 02215, United States\|Mayo Clinic, Rochester, Minnesota, 55905, United States\|Washington University, Saint Louis, Missouri, 63110, United States\|Cornell University Weill Medical College, New York, New York, 10065, United States\|Memorial Sloan-Kettering Cancer Center - NYC, New York, New York, 10065, United States\|Cleveland Clinic, Cleveland, Ohio, 44195, United States\|Ohio State University, Gahanna, Ohio, 43230, United States\|Oregon Health and Science University OHSU, Portland, Oregon, 97239, United States\|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, 37203, United States\|Ut Southwestern Medical Center At Dallas, Dallas, Texas, 75390-85520, United States\|MD Anderson Cancer Center, Houston, Texas, 77030, United States\|Local Institution - 202, Bordeaux, 33076, France\|Local Institution - 204, Paris, 75010, France\|Local Institution - 203, Pessac, 33604, France\|Local Institution - 205, Toulouse, 31059, France\|Local Institution - 201, Villejuif, 94805, France Less <<
NCT04522895	Leukemia, Myeloid, Acute\|Myelo... More >>dysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|IDH2 Gene Mutation\|IDH2 R172\|IDH2 R140 Less <<	PHASE2	COMPLETED	2024-07-24	University Hospital Duesseldor... More >>f Dept. of Hematology, Oncology and Clinical Immunology, Duesseldorf, NRW, 40225, Germany\|Uniklinik RWTH Aachen Klinik für H?matologie, Onkologie, H?mostaseologie und Stammzelltransplantation (Med. Klinik IV), Aachen, 52074, Germany\|Universit?tsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik I, Dresden, 01307, Germany\|Universit?tsklinikum Essen Klinik für H?matologie und Stammzelltransplantation, Essen, 45147, Germany\|Universit?tsklinikum Frankfurt Med. Klinik II, Frankfurt, 60590, Germany\|Universit?tsklinikum Hamburg-Eppendorf Interdisziplin?re Klinik für Stammzelltransplantation, Hamburg, 20246, Germany\|Universit?tsklinikum Heidelberg Innere Medizin V: H?matologie, Onkologie und Rheumatologie, Heidelberg, 69120, Germany\|Universit?tsklinikum K?ln Klinik I für Innere Medizin, K?ln, 50937, Germany\|Universit?tsklinikum Leipzig Medizinische Klinik und Poliklinik I, H?matologie und Zelltherapie, Leipzig, 04103, Germany\|Klinikum rechts der Isar der TU München Klinik und Poliklinik für Innere Medizin III, H?matologie und Onkologie, München, 81675, Germany\|Universit?tsklinikum Münster Medizinische Klinik A / KMT Zentrum, Münster, 48149, Germany Less <<
NCT02273739	Solid Tumor\|Glioma\|Angioimmuno... More >>blastic T-cell Lymphoma\|Intrahepatic Cholangiocarcinoma\|Chondrosarcoma Less <<	PHASE1\|PHASE2	COMPLETED	2016-06-03	Los Angeles, California, 90095... More >>, United States\|Los Angeles, California, 91010, United States\|Miami, Florida, 33136, United States\|Baltimore, Maryland, 21287, United States\|Boston, Massachusetts, 02114, United States\|Omaha, Nebraska, 68198, United States\|New York, New York, 10065, United States\|Cleveland, Ohio, 44195, United States\|Nashville, Tennessee, 37203, United States\|Dallas, Texas, 75390, United States\|Bordeaux, 61283 33076, France\|Villejuif Cedex, 94805, France Less <<
NCT06240754	Clonal Cytopenia of Undetermin... More >>ed Significance\|CCUS Clonal Cytopenia of Undetermined Significance Less <<	PHASE2	RECRUITING	2026-10-31	Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT02387866	Healthy	PHASE1	COMPLETED	2015-07-27	Parexel International, Glendal... More >>e, California, 91206, United States Less <<
NCT03290443	Hepatic Impairment	PHASE1	COMPLETED	2018-10-26	DaVita Clinical Research, Lake... More >>wood, Colorado, 80228, United States\|Clinical Pharmacology of Miami, LLC, Miami, Florida, 33014-3616, United States\|Orlando Clinical Research Center OCRC, Orlando, Florida, 32809, United States\|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States\|New Orleans Center of Clinical Research, Knoxville, Tennessee, 37920, United States Less <<
NCT04310527	Healthy Volunteers	PHASE1	COMPLETED	2019-12-09	PPD Development, LP, Austin, T... More >>exas, 78744, United States Less <<
NCT03723057	Acute Myeloid Leukemia		NO_LONGER_AVAILABLE	-	Celgene, Summit, New Jersey, 0... More >>7901, United States Less <<
NCT06176989	Metastatic Chondrosarcoma\|Loca... More >>lly Advanced Chondrosarcoma\|Metastatic Sinonasal Adenocarcinoma\|Locally Advanced Sinonasal Adenocarcinoma\|Metastatic Large-cell Neuroendocrine Carcinoma\|Locally Advanced Large-cell Neuroendocrine Carcinoma\|Metastatic Olfactory Neuroblastoma\|Locally Advanced Olfactory Neuroblastoma\|Metastatic Sinonasal Undifferentiated Carcinoma\|Locally Advanced Sinonasal Undifferentiated Carcinoma Less <<	PHASE2	RECRUITING	2030-12-31	National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.11mL 0.42mL 0.21mL	10.56mL 2.11mL 1.06mL	21.12mL 4.22mL 2.11mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed